MedTrace Logo

Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

NCT03405194 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-03-18

No results posted yet for this study

Summary

Randomized, open-label study comparing Elvitegravir-Cobicistat-Tenofovir Alafenamide-Emtricitabine (Genvoya) vs. Efavirenz-Tenofovir Disoproxil Fumarate-Lamivudine (EFV-TDF-3TC) in patients starting ART on the day of HIV diagnosis.

Conditions

Interventions

DRUG

Elvitegravir, Cobicistat, TAF, FTC

Started on day of HIV diagnosis

DRUG

Efavirenz, TDF, and 3TC

Started on day of HIV diagnosis

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Analysis Group, Inc.

    collaborator INDUSTRY

  • Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic

    lead OTHER

Principal Investigators

  • Jean W Pape, MD · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic

  • Serena P Koenig, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-05-01
Completion
2020-07-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03405194 on ClinicalTrials.gov